A drug house founded in London by two American pharmacists.

Sudafed is a brand name and registered trademark for over-the-counter nasal decongestants, English Wikipedia says, sold in the United States, Canada, the United Kingdom, Ireland, Australia, New Zealand and South Africa. Its owner today is Kenvue, the consumer-health company separated from Johnson & Johnson. Before that, the name passed through several companies.

By the early 1990s Sudafed belonged to Burroughs Wellcome & Co., the drug house that the American pharmacists Henry Wellcome and Silas Burroughs founded in London in 1880, according to English Wikipedia’s history of its successor, GSK. The same account says Burroughs Wellcome set up research and manufacturing in Tuckahoe, New York, in the 1920s, and that its American headquarters stayed there until 1971, when the company moved to Research Triangle Park in North Carolina, into a building designed by the architect Paul Rudolph.

In the summer of 1993 Sudafed appears in print as one of Burroughs Wellcome’s over-the-counter names. The Tan Sheet, a consumer-health newsletter now archived by the Pink Sheet, reported on 2 August 1993 that a letter of intent announced on 28 July would combine the over-the-counter products of Warner-Lambert and Burroughs Wellcome in a new business called Warner-Wellcome Consumer Health Products. The newsletter listed Burroughs Wellcome’s brands as Actifed, Sudafed, Neosporin and Nix, set against Warner-Lambert names including Benadryl, Efferdent, Lubriderm and Listerine.

The Pharma Letter reported on 5 June 1994 that the two companies had finalized the arrangement begun with the letter of intent of July 1993, setting up joint-venture companies under the Warner Wellcome name to develop and market over-the-counter medicines in the United States and in Europe, with Warner-Lambert holding the larger share of the American venture and the European venture split equally.

From Warner-Lambert to Johnson & Johnson.

The joint venture did not last long. Glaxo and Wellcome merged in 1995 to form Glaxo Wellcome, English Wikipedia says, and The Pink Sheet reported in its issue of 1 January 1996 that Glaxo Wellcome had announced on 19 December 1995 that it was divesting its interest in the Warner-Wellcome joint venture. The paper described the deal as the sale of the former Wellcome over-the-counter product line to Warner-Lambert, and said the former Burroughs Wellcome manufacturing plant at Greenville, North Carolina, would be put up for sale as a result. Glaxo Wellcome itself merged with SmithKline Beecham in 2000 to form GSK, English Wikipedia says.

Warner-Lambert changed hands at the turn of the century. In February 2000, English Wikipedia says, Pfizer bought Warner-Lambert along with its subsidiary companies. English Wikipedia’s Sudafed article records that in late 2004 Pfizer disclosed plans for a new product, Sudafed PE, made without pseudoephedrine, and says the product was prompted by existing and proposed restrictions on pseudoephedrine products. In the United States the Combat Methamphetamine Epidemic Act, signed on 6 March 2006, set new sales rules for pseudoephedrine, and English Wikipedia says the original Sudafed is now sold from behind the pharmacy counter.

Pfizer’s ownership ended later in 2006. The Pink Sheet reported that on 20 December 2006 Johnson & Johnson announced it had closed its acquisition of Pfizer Consumer Healthcare, a deal the Federal Trade Commission had cleared on 12 December, and named Listerine, Nicorette and Sudafed among the brands included. English Wikipedia names McNeil Laboratories, a Johnson & Johnson division, as the maker of Sudafed in the countries where it is sold.

The brand’s range differs by country. In the United Kingdom, English Wikipedia says, the name covers products such as Sudafed Decongestant, Sudafed Blocked Nose Spray and Sudafed Sinus Pressure & Pain; in the United States it lists Sudafed PE and Sudafed OM, a nasal spray.

Design and documentation.

The medicine cabinet is a rule-bound place for a packaging designer to work. A pharmacy-aisle carton has to carry a brand name, a product name and a product category on its front face, and it has to do so beside text whose wording, order and minimum type size are set by a regulator rather than by the designer. In the United States that text is the Drug Facts panel, a fixed sequence of headings in a prescribed layout, and every carton, bottle label and blister card in the category has to make room for it.

That leaves the designer a narrower field than in many consumer categories: colour blocking, a wordmark, a band or stripe that signals a line extension, and the shape of the pack itself. Blister packs add a second printed surface, the foil backing. Bottles and caps carry the same system at a smaller scale.

Each guide that follows looks at who started a brand, who has owned it since, and how its cartons, labels and advertising have changed, and it describes products only by name and category as the company lists them.

A Kenvue brand since 2023.

The latest move came with Johnson & Johnson’s separation of its consumer business. English Wikipedia’s Kenvue article says Johnson & Johnson announced in November 2021 that it would spin off its consumer-health division, that the new company was named Kenvue in September 2022, and that its initial public offering took place in May 2023, with Johnson & Johnson completing a full separation through a share exchange later in 2023. Kenvue is headquartered in Summit, New Jersey, the same article says.

The brand’s own websites carry the result. An August 2026 snapshot of sudafed.com in the Internet Archive shows the American site published by Kenvue Brands LLC, and a March 2026 snapshot of sudafed.co.uk shows the British site published by Kenvue UK Limited. The American site sets the name in capital letters, as SUDAFED®, and lists products under it including Sinus Congestion 12 Hour decongestant caplets and a non-medicated saline nasal mist.

A further change of ownership has been announced. Kimberly-Clark and Kenvue announced an agreement under which Kimberly-Clark would acquire all of Kenvue’s shares, the New Zealand trade title Supermarket News reported on 5 November 2025, with the transaction expected to close in the second half of 2026, subject to approvals. Pulp & Paper News reported on 30 January 2026 that shareholders of both companies had voted to approve the deal at special meetings.

For a design guide, Sudafed shows a medicine-cabinet name that has passed from a London-founded drug house through a joint venture, Warner-Lambert, Pfizer and Johnson & Johnson to Kenvue. Compare Listerine, which was listed with Sudafed in the 1993 Warner-Wellcome plan, and Tylenol, another Kenvue brand. For this guide we use a decongestant red, deep navy and white with a grotesque sans, an unofficial interpretation; no product or logo is reproduced.

Keep Sudafed’s identity on hand — save it to a board in the Made Good inspiration library.